Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Go back to Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
AGENUS (NASDAQ: AGEN) Delayed: 7.79 -0.45 (5.46%)
Previous Close $8.24    52 Week High $7.49 
Open $8.14    52 Week Low $2.61 
Day High $8.18    P/E N/A 
Day Low $7.73    EPS $-1.10 
Volume 273,568